Vol 2, No 3 (2017)
Case report
Published online: 2017-12-28

open access

Page views 829
Article views/downloads 1092
Get Citation

Connect on Social Media

Connect on Social Media

Diagnosis and management of a patient with idiopathic macular telangiectasia type 2

Ioannis Mallias1, Panagiota Mylova, Anastasia Tassiopoulou
Ophthalmol J 2017;2(3):83-86.

Abstract

This is a case report discussing the case of a patient with idiopathic macular telangiectasia type 2. The diagnosis and the management of the patient are analysed as well as the possible factors that attribute to the appearance of idiopathic macular telangiectasia.

Article available in PDF format

View PDF Download PDF file

References

  1. Wu L, Evans T, Arevalo JF. Idiopathic macular telangiectasia type 2 (idiopathic juxtafoveolar retinal telangiectasis type 2A, Mac Tel 2). Surv Ophthalmol. 2013; 58(6): 536–559.
  2. Clemons TE, Gillies MC, Chew EY, et al. Macular Telangiectasia Project Research Group. Medical characteristics of patients with macular telangiectasia type 2 (MacTel Type 2) MacTel project report no. 3. Ophthalmic Epidemiol. 2013; 20(2): 109–113.
  3. Sallo FB, Leung I, Zeimer M, et al. MacTel Study Group. Abnormal retinal reflectivity to short-wavelength light in type 2 idiopathic macular telangiectasia. Retina. 2017 [Epub ahead of print].
  4. Heeren TFC, Clemons T, Scholl HPN, et al. Progression of vision loss in macular telangiectasia type 2. Invest Ophthalmol Vis Sci. 2015; 56(6): 3905–3912.
  5. Sallo FB, Leung I, Clemons TE, et al. MacTel CNTF Research Group. Correlation of structural and functional outcome measures in a phase one trial of ciliary neurotrophic factor in type 2 idiopathic macular telangiectasia. Retina. 2017 [Epub ahead of print].
  6. Gonzalez MA, Shechtman D, Haynie JM, et al. Unveiling idiopathic macular telangiectasia: clinical applications of optical coherence tomography angiography. Eur J Ophthalmol. 2017; 27(4): e129–e133.
  7. Chidambara L, Gadde SGK, Yadav NK, et al. Characteristics and quantification of vascular changes in macular telangiectasia type 2 on optical coherence tomography angiography. Br J Ophthalmol. 2016; 100(11): 1482–1488.
  8. Toto L, Di Antonio L, Mastropasqua R, et al. Multimodal imaging of macular telangiectasia type 2: Focus on vascular changes using optical coherence tomography angiography. Invest Ophthalmol Vis Sci. 2016; 57(9): OCT268–OCT276.
  9. Alkin Z, Yilmaz I, Ozkaya A, et al. Anti-vascular endothelial growth factor treatment for proliferative macular telangiectasia type 2. Middle East Afr J Ophthalmol. 2016; 23(2): 222–224.
  10. Chhablani J, Dedhia CJ, Peguda HK, et al. Short-term safety of 2 mg intravitreal ziv-aflibercept. Retina. 2017; 37(10): 1859–1865.
  11. Aydoğan T, Erdoğan G, Ünlü C, et al. Intravitreal bevacizumab treatment in type 2 idiopathic macular telangiectasia. Turk J Ophthalmol. 2016; 46(6): 270–273.
  12. Toygar O, Guess MG, Youssef DS, et al. Long-term outcomes of intravitreal bevacizumab therapy for subretinal neovascularization secondary to idiopathic macular telangiectasia type 2. Retina. 2016; 36(11): 2150–2157.
  13. Gass JD, Oyakawa RT. Idiopathic juxtafoveolar retinal telangiectasis. Arch Ophthalmol. 1982; 100(5): 769–780.
  14. Gass JD, Blodi BA. Idiopathic juxtafoveolar retinal telangiectasis. Update of classification and follow-up study. Ophthalmology. 1993; 100(10): 1536–1546.
  15. Gamulescu MA, Walter A, Sachs H, et al. Bevacizumab in the treatment of idiopathic macular telangiectasia. Graefes Arch Clin Exp Ophthalmol. 2008; 246(8): 1189–1193.
  16. Charbel Issa P, Finger RP, Kruse K, et al. Monthly ranibizumab for nonproliferative macular telangiectasia type 2: a 12-month prospective study. Am J Ophthalmol. 2011; 151(5): 876–886.e1.
  17. Wilson C. Treatment with intravitreal steroid reduces blood-retinal barrier breakdown due to retinal photocoagulation. Archives of Ophthalmology. 1992; 110(8): 1155.
  18. Edelman JL, Lutz D, Castro MR. Corticosteroids inhibit VEGF-induced vascular leakage in a rabbit model of blood-retinal and blood-aqueous barrier breakdown. Exp Eye Res. 2005; 80(2): 249–258.